Where Have the Periods Gone? The Evaluation and Management of Functional Hypothalamic Amenorrhea

© Marie Eve Sophie Gibson¹, Nathalie Fleming², Caroline Zuijdijk², Tania Dumont¹

¹University of Ottawa, Children’s Hospital of Eastern Ontario, Division of Gynecology, Ottawa, Canada
²University of Ottawa, Children’s Hospital of Eastern Ontario, Division of Endocrinology and Metabolism, Ottawa, Canada

Abstract

Functional hypothalamic amenorrhea (FHA) is common and is often seen in the setting of stress, weight loss, or excessive exercise. FHA is a diagnosis of exclusion. Patients with primary or secondary amenorrhea should be evaluated for other causes of amenorrhea before a diagnosis of FHA can be made. The evaluation typically consists of a thorough history and physical examination as well as endocrinological and radiological investigations. FHA, if prolonged, can have significant impacts on metabolic, bone, cardiovascular, mental, and reproductive health. This article will highlight what is known about the pathophysiology of FHA, as well as the necessary steps in evaluating a patient for FHA, and the important aspects of its management.

Keywords: Adolescent, diagnosis, functional, hypothalamic amenorrhea, treatment

Introduction

Functional hypothalamic amenorrhea (FHA) is defined as the absence of menses, caused by a suppression of the hypothalamic-pituitary-ovarian (HPO) axis, in which no anatomic or organic cause is found (1). It is potentially reversible, and is often seen in the setting of stress, weight loss, or excessive exercise (1,2,3). FHA can present as either primary or secondary amenorrhea. Primary amenorrhea is defined as the absence of menarche by age 15 in the presence of mature breast development, or three years after thelarche (4). Delayed puberty is defined as the absence of thelarche by the age of 13 (4). Secondary amenorrhea is defined as the absence of menses for more than three cycles in someone who was previously menstruating regularly, or longer than six months in someone with irregular cycles (5,6). FHA is the most common form of primary and secondary amenorrhea in adolescent girls (7). With specific regard to secondary amenorrhea, FHA and polycystic ovarian syndrome (PCOS) are the most common causes, other than pregnancy (1). If prolonged, FHA has potential consequences for metabolic, bone, cardiovascular, mental, and reproductive health. This article will highlight what is known about the pathophysiology of FHA, as well as the necessary steps in evaluating a patient for FHA, and the important aspects of its management.

Pathophysiology

FHA is caused by a suppression of the HPO axis. In normal puberty, gonadotropin-releasing hormone (GnRH) is released by the hypothalamus in a pulsatile fashion, and stimulates both the synthesis and secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary (7). In patients with FHA, studies have shown that GnRH secretion is suppressed, LH pulsatility is impaired (8,9,10,11), and total LH and FSH levels are reduced (11,12,13,14). FHA is therefore classified as a form of hypogonadotropic hypogonadism, which results in a hypoestrogenic state (8,12,13,14). In FHA, suppression of the HPO axis is caused by common triggers including psychological stress, disordered eating, weight loss, and excessive exercise (1,2,3).

Though amenorrhea is often associated with eating disorders such as anorexia nervosa, FHA is often found to be the underlying etiology for amenorrheic patients who...
maintain 90-110% of their ideal body weight (IBW) and who do not meet diagnostic criteria for an eating disorder (15). IBW is calculated by the Devine formula [IBW (kg) = 45.5 kg + 2.3 kg for each inch over 5 feet] (16) or can be determined by standardized height and weight tables such as the Metropolitan Life tables (17). Disordered eating is quite common in adolescent girls. In a cross-sectional study of grade 10 girls, 4.1% of girls sampled met the criteria for secondary amenorrhea and 23% disclosed disordered eating. Of the girls with amenorrhea, 40% reported fasting or purging. Interestingly, body mass index (BMI) (BMI; kg/m²) was not significantly different between those who were eumenorrheic or amenorrheic (18). Studies have shown that patients with FHA exhibit more cognitive restraint (19), drive for thinness (12,19,20,21), and purging behaviours (21,22) compared to eumenorrheic controls.

Excessive exercise has been linked to the development of FHA (23,24). In one study, rates of secondary amenorrhea were three times higher in athletes compared to controls, with the highest rates seen in long distance runners (25). Since the early 1990s, the Female Athlete Triad (FAT) has been used to describe athletes who also present with disordered eating, osteoporosis, and amenorrhea (26). In 2017, the American College of Obstetricians and Gynecologists revised the definition of FAT to be more inclusive. The criteria are now: low energy availability with or without disordered eating, menstrual dysfunction, and low bone density (27). Though the menstrual dysfunction in FAT is thought to be hypothalamic in nature, FAT differs from FHA because athletes are not required to be amenorrheic to meet criteria for FAT. Moreover, not all patients with FHA are athletes or meet the criteria for FAT.

Onset of amenorrhea can also be seen in the setting of stress (12,28,29,30). In a study of adolescent girls with FHA, identified stressors included common life events such as changing schools, newly engaging in sexual activity, and breaking up with a boyfriend. Chronic illness of a family member and the death of a friend were also observed. Lastly, 50% of the adolescents in this study described family conflict (12). Patients with FHA have also been shown to cope less well with stress, including their autonomic responses, compared to those with PCOS and eumenorrheic controls (31).

Lastly, there may also be a genetic basis to the development of FHA. One study identified six heterozygous gene mutations in patients with FHA that are shared among patients who have congenital (idiopathic) hypogonadotropic hypogonadism, suggesting a possible vulnerability to the effects of stressors on the HPO axis. Mutations found involved the fibroblast growth factor receptor 1 gene FGFR, the prokineticin receptor 2 gene PROKR2, the GnRH receptor gene GNRHR, and the Kallmann syndrome 1 sequence gene KAL1. Such mutations were not found in healthy controls (32).

Regardless of the trigger for FHA, a common hypothesis is that an increase in corticotropin-releasing hormone (CRH), in response to stress, suppresses GnRH pulsatility (10). Patients with FHA have increased cortisol levels (10,12,13,14,20,29,33), as well as blunted responses to the injection of human CRH (hCRH) (15,29,33). In addition, the neurotransmitter γ-aminobutyric acid has also been linked to suppression of GnRH (13). Thyroid hormone changes are also noted in FHA. Patients with FHA tend to have lower total triiodothyronine (T3) and total thyroxine (T4) concentrations compared to eumenorrheic controls (11,34). However, their concentrations of free T3 and T4 may remain intact due to lower affinity of thyroid binding globulin (34). Thyroid-stimulating hormone (TSH) levels typically remain normal (11,14,34) and patients appear to be clinically euthyroid (34). Metabolic disturbances are also observed, with decreased leptin (8,12,14,19,35,36), decreased fasting insulin (12,14,35), decreased insulin-like growth factor-1 (IGF-1) (8,12), increased fasting peptide YY (19), and increased fasting ghrelin in patients with FHA (19,22). These changes reflect the overall energy deficit in patients with FHA.

**Diagnosis of FHA**

The diagnosis of FHA can be challenging in adolescents, as this is commonly a time when the HPO axis is developing. However, primary amenorrhea should always be investigated, as 98% of girls will achieve menarche by the age of 15 (37). Furthermore, 90% of menstrual cycles will range between 21-45 days, even in the first few postmenarchal years (38), highlighting the importance of investigating secondary amenorrhea in this age group. As FHA is a non-organic cause of amenorrhea, it is often considered a diagnosis of exclusion. Table 1 summarizes the vast differential diagnoses of amenorrhea, which should be taken into consideration.

**History:** A pubertal history should include onset and timing of breast and pubic hair development, as well as growth spurt. A detailed menstrual history should be obtained to characterize the type of amenorrhea and its onset. One should look for possible triggers including stressful life events, disordered eating, weight loss (regardless of initial weight), or excessive exercise. Disordered eating can include avoidance of certain foods (typically foods high in fat, sugar, and calories), restricting, and/or purging (self-induced vomiting, laxative
A diet log can be helpful. If weight loss has been identified as a contributing factor, it is important to note the weight at which the patient became amenorrheic and the tempo of the weight loss. Lastly, it is important to inquire about how the weight loss was achieved, as well as how they feel about the weight loss, as this helps determine whether a formal eating disorder diagnosis should be considered. The type of exercise should be noted, as well as the duration and intensity. Patients should be asked about their past medical history, including chronic illness or malignancy. A list of medications should be obtained, and previous or current treatments with chemotherapy or radiation should be noted. A sexual history, taken alone with the adolescent in complete privacy, should be obtained, including use of contraceptives. On review of symptoms, patients should be asked about possible associated symptoms in a head to toe approach. To reiterate, one should ask about possible triggers affecting the hypothalamus, such as stress, disordered eating, weight loss, or excessive exercise. Headaches, visual disturbances, or galactorrhea could suggest the presence of a prolactinoma or another central nervous system disorder. A history of anosmia could point to Kallman syndrome. Changes in energy, temperature regulation, or bowel movement frequency could be related to an underlying thyroid disorder. Patients should be asked about signs of hyperandrogenism, such as acne or hirsutism, as this could point to a diagnosis of PCOS or late-onset congenital adrenal hyperplasia. More significant virilization (clitoromegaly, severe hirsutism, voice changes) could point to an androgen secreting tumour of either adrenal or ovarian origin. Vasomotor symptoms such as hot flashes or night sweats could be indicative of primary ovarian insufficiency (POI). Inquire about symptoms of pregnancy, such as weight gain, nausea, fatigue, vomiting, or breast tenderness. Abdominal pain, either cyclic or chronic, could indicate a possible Müllerian anomaly. Lastly, a thorough family history, including the menstrual history of the biological mother, should be obtained. Questions about possible triggers and sexual history should be reserved for the confidential portion of the interview. Commonly, the “Home environment, Education and employment, Eating, peer-related Activities, Drugs, Sexuality, Suicide/depression, and Safety from injury and violence-HEEADSSS” format is used (39).

**Physical examination:** The physical examination should first begin with a general inspection of the patient’s well-being. The patient’s height and weight should be measured and plotted on growth curves that ideally have previously been completed by the referring or primary care provider in order to facilitate comparisons and trends. The BMI (kg/m²) should be calculated and plotted. Vital signs should

### Table 1. Differential diagnosis of amenorrhea

| Category | Condition |
|----------|-----------|
| **Constitutional delay** | - Hypothalamus: Central nervous system lesion (hydrocephalus, tumor), Chronic medical illness, Congenital hypogonadotropic hypogonadism (Kallman syndrome), FHA (stress, weight loss, disordered eating, exercise) |
| **Pituitary** | Congenital hypogonadotropic hypogonadism, Empty Sella syndrome, Hyperprolactinemia, Iatrogenic (surgery, radiation), Infarction (Sheehan syndrome), Infiltrative disease |
| **Thyroid** | Hyperthyroidism, Hypothyroidism |
| **Adrenal** | Adrenal insufficiency, Androgen-secreting tumor, CAH, Cushing syndrome |
| **Ovary** | Androgen-secreting tumor, Gonadal agenesis or dysgenesis (ex. Turner syndrome, Swyer syndrome), Iatrogenic (surgery, radiation), Medications (antiandrogens, contraceptives) |
| **PCOS** | POI |
| **Uterus** | Adhesions (Asherman syndrome), Levonorgestrel IUS, Müllerian anomaly, Pregnancy |
| **Outflow tract** | Cervical agenesis, Cervical stenosis (acquired), Imperforate hymen, Vaginal agenesis, Vaginal septum (transverse) |

CAH: congenital adrenal hyperplasia, PCOS: polycystic ovarian syndrome, POI: primary ovarian insufficiency, IUS: intrauterine system, FHA: functional hypothalamic amenorrhea, Ref. 1,3,6,41.
include blood pressure and heart rate. Hypertension and tachycardia can be seen in hyperthyroidism or Cushing syndrome, whereas hypotension and bradycardia can be seen in hypothyroidism, adrenal insufficiency, and severe eating disorders. Look for stigmata of Turner syndrome (low hairline, webbed neck, wide carrying angle, shield chest, and nevi, including facial nevi). Look for signs of restrictive or purging behaviours, which include cachexia, erosion of dental enamel, parotid gland swelling, vellus hair, Russell’s sign (calluses on the knuckles) and hypercarotenemia (yellowing of the skin). A visual field examination and fundoscopy is recommended, particularly if there are concerns regarding central nervous system symptoms in the history. Palpate the thyroid gland for a goiter or nodules and examine for other signs of thyroid disease (exophthalmos or proposis, lid lag, hair or nail changes). Palpate the abdomen for masses. Look for signs of insulin resistance (acanthosis nigricans), hyperandrogenism (acne or hirsutism), or virilization (male pattern hair loss, change in muscle mass distribution, clitoromegaly, or voice deepening). Complete Tanner staging should be done to document pubertal development (40). The papilla and surrounding breast may also be examined for residual signs of galactorrhea. Perform an external genital examination with the aid of labial traction to assess for a patent hymen and lower vagina. This examination can also aid in determining the extent of estrogenization of the vulva. Typically, a reddened and thin hymen is seen in an estrogen-deficient state, whereas a light pink and plumper hymen is seen in the presence of adequate estrogen levels. The presence of leukorrhea can also point to adequate estrogenization. Lastly, a bimanual examination can be performed in patients who are sexually active, to palpate for a uterus and to rule out an adnexal mass. Typically, patients with FHA will have a physical examination within normal limits.

Endocrinological investigations: Initial blood work-up should include measurement of the beta subunit of human chorionic gonadotropin concentration, regardless of the disclosed sexual history, to rule out pregnancy. FSH, LH, estradiol, prolactin, and TSH concentrations should also be measured routinely. If there are signs of hyperandrogenism on examination, an androgen panel should be ordered, including total and free testosterone, androstenedione, and dehydroepiandrosterone sulfate, along with a 17-hydroxyprogesterone concentration, preferably in the early morning (1,3,41). Assessment of cortisol status may also be considered, based on presenting features. See Table 2 for a summary of laboratory findings in FHA.

A progesterone withdrawal challenge can be given to aid in the diagnosis. Five to 10 mg of medroxyprogesterone acetate are given for five to 10 days, after which the patient should experience a withdrawal bleed (41). A positive test is indicated by vaginal bleeding within two to seven days of completing the course of progestin (6). A negative test, or a lack of bleeding, may suggest an outflow tract abnormality or a hypoestrogenic state, as estrogen is responsible for thickening the endometrial lining (43). Scant withdrawal bleeding or spotting suggests marginal levels of endogenous estrogen production (6). Unfortunately, experts caution routine use of the progesterone withdrawal challenge, as it may be unreliable in determining the degree of estrogenization as this test is associated with false negative withdrawals (1,3,43,44).

Radiological investigations: An ultrasound of the pelvis is helpful to identify the presence of a uterus and ovaries, and to rule out an adnexal mass. If a Müllerian anomaly is suspected, magnetic resonance imaging (MRI) of the pelvis, or a 3D transvaginal ultrasound, if the patient is coitarchal, may better characterize the specific anomaly (45,46,47). Head imaging with computed tomography or MRI is not typically required unless the adolescent girl presents with galactorrhea (± hyperprolactinemia), headaches or visual disturbances, suggesting a possible intracranial lesion (1,41,48). It may also be indicated if there is a negative progesterone withdrawal challenge (4).

Due to the risk of osteopenia and osteoporosis associated with hypoestrogenism, patients with prolonged amenorrhea, of six months or more, should be considered for baseline bone mineral density (BMD) assessment measured by dual-energy X-ray absorptiometry (DEXA/DXA) scan and lateral spine radiograph to assess for asymptomatic vertebral fractures (15,41,49,50,51,52,53). In adolescents,
Management

The menstrual cycle has been recognized as an important vital sign in adolescent girls (55,56), and the absence of menses may be an indication of compromised overall health. As such, the main goal of management in FHA is the resumption of menses.

Lifestyle modification: Addressing possible triggers such as weight loss, disordered eating, or excessive exercise is a primary focus in the management of FHA. In one study by Kondoh et al (29), patients with FHA related to psychogenic stress, aged 15-33, were treated with psychoeducation which focused on stress management. A greater proportion of these patients recovered compared to those with weight-associated FHA; 81.8% versus 54.0%. Their average time to recovery was also slightly shorter at 17.2±4.1 months versus 19.4±5.0 months. A small randomized controlled trial (RCT) looked at the effect of a 20-week intervention with cognitive based therapy (CBT) in patients with FHA (61). In this study, the eight patients randomized to the CBT arm had a higher rate of ovarian activity (87.5%) compared to those eight patients that were in the observation arm (25.0%). Ovarian activity was determined by measuring plasma estradiol and progesterone levels, in order to confirm ovulation. BMI did not significantly change during the intervention. CBT has also been shown to have an impact on metabolic health in these patients. In a follow-up study by Michopoulos et al (62), patients randomized to the CBT arm had an improvement in cortisol, TSH, and leptin concentrations compared to those in the observation arm.

Other forms of psychological therapy have been studied. In a small prospective study, 12 patients with FHA, aged 20-33, were given a 45-70 minute hypnotherapy session and then observed for 12 weeks (63). Nine patients (75%) resumed menses, and one patient became pregnant during this time.
All patients also reported increased general well-being and improved self confidence.

Though studies looking at psychological therapy in FHA have been small, the effects of therapy are promising and are unlikely to result in harm. Therefore, psychological therapy may be considered as part of the multidisciplinary treatment of patients with FHA.

**Pharmacological therapy:** The main role of pharmacological therapy in FHA is to promote bone health and prevent the development of osteoporosis. A lack of estrogen during premenopausal years has been linked to decreased BMD. This is based on studies looking at the outcomes of premenopausal women undergoing bilateral oophorectomy (64,65). In one study, vertebral bone loss could be detected as early as six months post-operatively (64). An increase in the frequency of fragility fractures of the radius and femoral neck was also observed (65). Similarly, in patients with FHA, the associated hypoestrogenic state can result in reduced bone density (15,50,51). In young women less than 20 years of age, missing even 50% of menstrual cycles can result in a significant decrease in BMD (52). Therefore, studies have looked at the effects of hormone replacement therapy on BMD in patients with FHA.

A systematic review by Liu and Lebrun (66) summarized ten studies evaluating the impact of hormone therapy on BMD in women with FHA. They found seven studies which demonstrated a positive effect of combined oral contraceptives (COCs) on BMD (67,68,69,70,71,72,73), two studies that showed no effect (74,75), and one case report where a negative effect was observed (76). Of the studies that showed a positive effect, two were small RCTs (67,68). Hergenroeder et al (67) showed a significant increase in both the total BMD and lumbar spine BMD of five patients receiving 35 µg ethinyl estradiol (EE) + 0.5-1 mg norethindrone, compared to five controls. Castelo-Branco et al (68) showed a significant increase in lumbar spine BMD in 24 patients taking 30 µg EE + 0.15 mg desogestrel and 22 patients taking 20 µg EE + 0.15 mg desogestrel, compared to 18 control patients who showed a decrease in BMD. Of the studies that showed no effect, one cohort study looking at female long distance runners, found no difference in BMD after one year in nine patients who started on a COC (75). However, in the same study 11 patients with FHA who were not using a COC showed a significant reduction in BMD over the same time period. Currently, the Endocrine Society has recommended against using COCs for the sole purpose of improving BMD, due to conflicting evidence. Instead, a trial of short-term transdermal estrogen with a cyclic oral progestin is recommended in amenorrheic adolescents who have not been successful with lifestyle modification, and who are not in need of COCs for contraception (41).

To date, the majority of evidence for the positive effects of transdermal estrogen on BMD comes from research involving patients with anorexia nervosa (77,78). However, its use in patients with FHA is attracting interest and has started to be studied. Zanker et al (76) published a case report of a 24-year-old amenorrheic athlete, whom they followed for 12 years. They measured her body weight every three months and her BMD by DXA every 11-13 months. After being on COCs for five years, the BMD of her lumbar spine and proximal femur declined by 9.8% and 12.1%, respectively. Her weight dropped concomitantly from 45.1 to 41.4 kg. Over the next 3.7 years, she was treated with transdermal estrogen and an oral progestin. Her lumbar spine BMD gradually increased by 9.4%, despite a further 0.8 kg decline of body mass. In the last 2.9 years of the study, she continued the transdermal estrogen, gained a total of 8.1 kg of body mass, and had a 16.9% increase in her proximal femur BMD. Furthermore, an RCT by Ackerman et al. (79) from 2019 showed an improvement in BMD in athletes with oligo-amenorrhoea receiving transdermal estrogen. In this study, 43 patients were randomized to receive a 100 mcg 17β-estradiol transdermal patch twice weekly with cyclic micronized progesterone (200 mg, 12 days per month), 40 patients to receive a daily pill with 30 µg EE + 0.15 mg desogestrel, and 38 patients received no hormonal treatment. All patients also received 800 IU of vitamin D and ≥1200 mg of calcium per day. BMD was assessed at baseline, six, and 12 months. Patients randomized to the patch arm had significantly higher spine and femoral neck BMD Z-scores at 12 months compared to the pill and the no treatment arm, and higher hip BMD Z-scores than the pill arm. The results of this landmark study are promising and lend support to the use of transdermal estrogen in patients with FHA.

In amenorrheic adolescents, 1200-1500 mg of calcium supplementation (80) as well as vitamin D 400-1000 IU (1) are recommended daily to support bone health. However, other therapies such as testosterone or bisphosphonates are not currently recommended to improve BMD in patients with FHA (41,81), as the literature available focuses mainly on patients with anorexia nervosa and the current evidence is limited.

**Fertility:** Patients with FHA may experience escape ovulation and therefore contraception is important if they do not desire pregnancy (41). In addition, adolescents with FHA may inquire about future fertility. Ovarian reserve is typically normal in these patients, as evidenced by their normal anti-Müllerian hormone (AMH) levels (42). In
patients who desire pregnancy, ovulation induction with pulsatile GnRH is the current gold standard (82,83,84,85). When compared to injectable gonadotropins, chances of conception are higher after six cycles of pulsatile GnRH at 96% versus 72% for injected gonadotropins based on life table analysis (82). Furthermore, injectable gonadotropins are associated with a higher rate of multiples (14.8% versus 9.3%), though the finding was not statistically significant (82). These results were more recently replicated in a study by Dumont et al (84) which showed a per patient conception rate of 65.8% with pulsatile GnRH versus 23.5% with gonadotropins. Though the trend favouring pulsatile GnRH is the same in both studies, the conception rates in the Dumont et al study are significantly lower. This may be explained by the differences in study populations between these studies, with lower BMI and baseline gonadotropin levels in the Dumont et al (84) study. The mean BMI in Dumont et al was 18.5 kg/m² (pulsatile GnRH group) and 18 kg/m² (gonadotropin group), whereas in Martin et al (82) it was 24.3 kg/m² (pulsatile GnRH group) and 24.5 kg/m² (gonadotropin group). Baseline LH, FSH, and estradiol levels were also lower in Dumont et al (84). Naltrexone, an opioid antagonist, has also been studied. GnRH secretion has been found to be suppressed by endogenous opioids (86). It was hypothesized that GnRH pulsatility could therefore be stimulated by opioid antagonism. Though naltrexone has been shown to increase GnRH pulsatility and increase rates of ovulation (86,87,88,89), its use has not become standard practice.

Cardiovascular considerations: Patients with prolonged FHA may be at higher risk of cardiovascular complications in the future (90). Studies in pre-menopausal adult women have shown hypothalamic hypoestrogenism is associated with a higher risk of coronary artery disease (91). Other possible effects include vascular endothelial dysfunction and reduced regional blood flow, as was shown in young amenorrheic athletes (92). These athletes were also found to have abnormal lipid profiles, including elevated total cholesterol and low-density lipoprotein cholesterol (92). As a follow-up study, Rickenlund et al (93) investigated the effects of using a COC (30 µg EE + 0.15 mg levonorgestrel) on these cardiovascular endpoints in amenorrheic athletes. While an improvement in vascular endothelial function after nine months of COC use was found, the lipid profile did not significantly change, with the exception of a small increase in high-density lipoprotein cholesterol. As this study was small, the authors indicated the need for larger, long-term studies to determine the clinical importance of their findings. As of now, the majority of recommendations surrounding cardiovascular health of patients with FHA focus on the lifestyle modifications that can be made to resume menses (90).

Novel therapies: Studies are now focusing on the underlying metabolic abnormalities within FHA to direct therapy. Small RCTs have looked at the effects of treatment with recombinant human leptin. Welt et al (94) demonstrated an improvement in serum estradiol, increased levels of free T4, and IGF-1 with administration of recombinant methionyl human leptin (r-metHuLeptin; starting dose 0.08 mg per kilogram of body weight per day) subcutaneously for two to three months. Three out of eight women (37.5%) resumed ovulatory cycles, which the authors stated was higher than the expected rate of spontaneous ovulation of 10%. In a small RCT, recombinant human leptin (metreleptin; starting dose 0.08 mg per kg of body weight per day) administered subcutaneously over 36 weeks, increased estradiol levels and decreased cortisol levels compared to placebo (95). Patients receiving recombinant human leptin in this study were also more likely to resume menses compared to controls (70% versus 22.2%). In both studies, markers of bone formation were also found to be increased, though BMD did not change significantly (94,95). The administration of kisspeptin has also been studied, and while acute administration appears to stimulate release of LH and FSH, chronic administration results in tachyphylaxis. Thus, the authors concluded that acute administration of kisspeptin may have therapeutic potential in patients with FHA (96). The Endocrine Society has recommended against the use of leptin or kisspeptin in the management of patients with FHA, as more research is needed in this area (41).

Conclusion

FHA is a common cause of both primary and secondary amenorrhea in adolescent girls. Common triggers include stress, weight loss, and excessive exercise. As FHA is a diagnosis of exclusion, a comprehensive workup should be performed to rule out anatomic and organic causes of amenorrhea. Prolonged FHA can have negative consequences on many aspects of a young women’s health, including metabolic, bone, cardiovascular, mental, and reproductive implications. The main goal in these patients is the resumption of menses. Lifestyle modifications are the first line focus for adolescent girls with FHA and a multidisciplinary approach, including a pediatric gynecologist and/or endocrinologist, pediatric sport psychologist, and sport dietician is beneficial. Pharmacological therapy can be considered in order to promote bone health, with transdermal estrogen being a promising option for patients. Further research on novel agents, such as recombinant
human leptin and kisspeptin, is required before considering their routine use in patients with FHA.

**Ethics**

**Peer-review:** Internally peer-reviewed.

**Authorship Contributions**

Literature Search: Marie Eve Sophie Gibson, Writing: Marie Eve Sophie Gibson, Nathalie Fleming, Caroline Zuijdwijk, Tania Dumont.

**Financial Disclosure:** The authors declared that this study received no financial support.

**References**

1. Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med 2010;363:365-371.
2. Meczekalski B, Podfigurna-Stopa A, Warenik-Szymankiewicz A, Genazzani AR. Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations. Gynecol Endocrinol 2008;24:4-11.
3. Klein DA, Poth MA. Amenorrhea: An approach to diagnosis and management. Am Fam Physician 2013;87:781-788.
4. Emans SJ, Laufer MR. Pediatric & Adolescent Gynecology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2012.
5. Rosenfield RL. Clinical review: Adolescent anovulation: Maturational mechanisms and implications. J Clin Endocrinol Metab 2013;98:3572-3583. Epub 2013 Aug 2
6. Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005;401-464.
7. Golden NH, Carlson JL. The pathophysiology of amenorrhea in the adolescent. Ann N Y Acad Sci 2008;1135:163-178.
8. Couzinet B, Young J, Brailly S, Le Bouc Y, Chanson P, Schaison G. Functional hypothalamic amenorrhea: a partial and reversible gonadotrophin deficiency of nutritional origin. Clin Endocrinol (Oxf) 1999;50:229-235.
9. Perkins RB, Hall JE, Martin KA. Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation. J Clin Endocrinol Metab 1999;84:1905-1911.
10. Suh BY, Liu JH, Berga SL, Quiqley ME, Laughlin GA, Yen SS. Hypercortisolism in patients with functional hypothalamic-amenorrhea. J Clin Endocrinol Metab 1998;83:733-739.
11. Berga SL, Morlina JF, Gitron L, Suh B, Laughlin G, Pham P, Yen SS. Neuroendocrine aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1989;68:301-308.
12. Bomba M, Gambera A, Bonini L, Peroni M, Neri P, Scagliola P, Nacinovich R. Endocrine profiles and neuropsychologic correlates of functional hypothalamic amenorrhea in adolescents. Fertil Steril 2007;87:876-885. Epub 2007 Jan 31
13. Meczekalski B, Tonetti A, Monteleone P, Bernardi F, Luisi S, Stomati M, Luisi M, Petragni F, Genazzani AR. Hypothalamic amenorrhea with normal body weight: ACTH, allopregnanolone and cortisol responses to corticotropin-releasing hormone test. Eur J Endocrinol 2000;142:280-285.
14. Andrico S, Gambera A, Specchia C, Pellegrini C, Falsetti L, Sartori E. Leptin in functional hypothalamic amenorrhea. Hum Reprod 2002;17:2043-2048.
15. Grinspoon S, Miller K, Coyle C, Krempin J, Armstrong C, Pitts S, Herzog D, Klibanski A. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 1999;84:2049-2055.
16. Devine B. Gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-655.
17. No authors listed. 1983 metropolitan height and weight tables. Stat Bull Metrop Life Found 1983;64:3-9.
18. Selzer R, Caust J, Hibbert M, Bowes G, Patton G. The association between secondary amenorrhea and common eating disordered weight control practices in an adolescent population. J Adolesc Health 1996;19:56-61.
19. Scheid JL, Williams NJ, West SL, VanHeest JL, De Souza MJ. Elevated PYY is associated with energy deficiency and indices of subclinical disordered eating in exercising women with hypothalamic amenorrhea. Appetite 2009;52:184-192. Epub 2008 Sep 25
20. Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998;83:25-32.
21. Marcus MD, Louchks TL, Berga SL. Psychological correlates of functional hypothalamic amenorrhea. Fertil Steril 2001;76:310-316.
22. Schneider LF, Warren MP. Functional hypothalamic amenorrhea is associated with elevated ghrelin and disordered eating. Fertil Steril 2006;86:1744-1749. Epub 2006 Oct 30
23. Ackerman KE, Misra M. Bone health and the Female Athlete Triad in adolescent athletes. Phys Sportsmed 2011;39:131-141.
24. Warren MP, Chua AT. Exercise-induced amenorrhea and bone health in the adolescent athlete. Ann N Y Acad Sci 2008;1135:244-252.
25. Dusek T. Influence of high intensity training on menstrual cycle disturbances in athletes. Croat Med J 2001;42:79-82.
26. Yeager KK, Agostini R, Nativ A, Drinkwater B. The female athlete triad: Disordered eating, amenorrhea, osteoporosis. Med Sci Sports Exerc 1993;25:775-777.
27. Committee on Adolescent Health Care. Committee Opinion No.702: Female Athlete Triad. Obstet Gynecol 2011;120:160-167.
28. Brown E, Bain J, Lerner P, Shaul D. Psychological, hormonal, and weight disturbances in functional amenorrhea. Can J Psychiatry 1983;28:624-628.
29. Kondoh Y, Uemura T, Murase M, Yokoi N, Ishikawa M, Hirahara F. A longitudinal study of disturbances of the hypothalamic-pituitary-adrenal axis in women with progestin-negative functional hypothalamic amenorrhea. Fertil Steril 2001;76:748-752.
30. Facchinetti F, Fava M, Fioroni L, Genazzani AD, Genazzani AR. Stressful life events and affective disorders inhibit pulsatile LH secretion in hypothalamic amenorrhea. Psychoneuroendocrinology 1993;18:397-404.
31. Gallinelli A, Matteo ML, Volpe A, Facchinetti F. Autonomic and neuroendocrine responses to stress in patients with functional hypothalamic secondary amenorrhea. Fertil Steril 2000;73:812-816.
32. Arconia LM, Martin C, Welt CK, Sykiotis GP, Quentin R, Thambudde A, Avbelj M, Dhruvakumar S, Plummer L, Hughes VA, Seminara SB, Boepple PA, Sidis Y, Crowley WF Jr, Martin KA, Hall JE, Pitteloud N. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med 2011;364:215-225.
33. Nappi RE, Petragni F, Genazzani AD, D’Ambrogio G, Zara C, Genazzani AR. Hypothalamic amenorrhea: evidence for a central derangement of hypothalamic-pituitary-adrenal cortex axis activity. Fertil Steril 1993;59:571-576.
34. Dominguez CE, Laughlin GA, Nelson JC, Yen SS. Altered binding of serum thyroid hormone to thyroxine-binding globulin in women with functional hypothalamic amenorrhea. Fertil Steril 1997;68:992-996.
35. Miller KK, Parulekar MS, Schoenfeld E, Anderson E, Hubbard J, Klibanski A, Garinsink SK. Decreased leptin levels in normal weight women with hypothalamic amenorrhea: The effects of body composition and nutritional intake. J Clin Endocrinol Metab 1998;83:2309-2312.

36. Warren MP, Voussoughian F, Geer EB, Hyle EP, Adberg CL, Ramos RH. Functional hypothalamic amenorrhea: Hypercortinemia and disordered eating. J Clin Endocrinol Metab 1999;84:873-877.

37. Chumlea WC, Schubert CM, Roche AF, Kulin HE, Lee PA, Himes JH, Sun SS. Age at menarche and racial comparisons in US girls. Pediatrics 2003;111:110-115.

38. No authors listed. World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care 1986;7:236-244.

39. Goldenberg JM, Rosen DS. Getting into adolescent heads: an essential update. Contemp Pediatr 2004;21:64.

40. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.

41. Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, Murad MH, Santoro NF, Warren MP. Functional hypothalamic amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 2017;102:1415-1459.

42. La Marca A, Pati M, Orvieto R, Carducci Artenisio A, Volpe A. Serum anti-müllerian hormone levels in women with secondary amenorrhea. Fertil Steril 2006;85:1547-1549. Epub 2006 Apr 17

43. Nakamura S, Douchi T, Oki T, Ijuin H, Yamamoto S, Nagata Y. Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding. Obstet Gynecol 1996;87:722-725.

44. Barick LD, Shangold MM, Ahmed SW. Cervical mucus and serum estradiol as predictors of response to progestin challenge. Fertil Steril 1990;54:353-355.

45. Olpin JD, Heilbrun M. Imaging of müllerian duct anomalies. Clin Obstet Gynecol 2009;52:40-56.

46. Berger A, Batzer F, Lev-Toaff A, Berry-Roberts C. Diagnostic imaging modalities for müllerian anomalies. The case for a new gold standard. J Minim Invasive Gynecol 2014;21:335-345. Epub 2013 Nov 15

47. Bermejo C, Martinez Ten P, Cantarero R, Diaz D, Perez Pedregosa J, Barrón E, Labrador E, Ruiz López L. Three-dimensional ultrasound in the diagnosis of Müllerian duct anomalies and concordance with magnetic resonance imaging. Ultrasound Obstet Gynecol 2010;35:593-601.

48. Acharya SV, Gopal RA, Bandgkar TR, Joshi SR, Menon PS, Shah NS. Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary 2008;12:186-189.

49. Miller KK, Klibanski A. Clinical review 106: Amenorrheic bone loss. J Clin Endocrinol Metab 1999;84:1775-1783.

50. Lawson EA, Donoho D, Miller KK, Misra M, Meenagh En, Lydecker J, Wexler T, Herzog DB, Klibanski A. Decreased leptin levels in normal weight women with hypothalamic amenorrhea: The effects of body composition and nutritional intake. J Clin Endocrinol Metab 1998;83:2309-2312.

51. Warren MP, Voussoughian F, Geer EB, Hyle EP, Adberg CL, Ramos RH. Functional hypothalamic amenorrhea: Hypercortinemia and disordered eating. J Clin Endocrinol Metab 1999;84:873-877.

52. Lloyd T, Myers C, Buchanan JR, Demers LM. Collegiate women athletes with irregular menses during adolescence have decreased bone density. Obstet Gynecol 1988;72:639-642.

53. Ward LM, Konji VN, Ma J. The management of osteoporosis in children. Osteoporos Int 2016;27:2147-2179. Epub 2016 Apr 28

54. Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N; International Society of Clinical Densitometry. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Position. J Clin Densitom 2014;17:275-280. Epub 2014 Mar 14

55. No authors listed. ACOG Committee Opinion No. 651: Menstruation in Girls and Adolescents: Using the Menstrual Cycle as a Vital Sign. Obstet Gynecol 2015;126:143-146.

56. Popat VB, Prodano T, Calis KA, Nelson LM. The menstrual cycle: a biological marker of general health in adolescents. Ann N Y Acad Sci 2008;1135:43-51.

57. Kopp-Woodroffe SA, Manore MM, Dueck CA, Skinner JS, Matt KS. Energy and nutrient status of amenorrheic athletes participating in a diet and exercise training intervention program. Int J Sport Nutr 1999;9:70-88.

58. Lindberg JS, Powell MR, Hunt MM, Ducey DE, Wade CE. Increased vertebral bone mineral in response to reduced exercise in amenorrheic runners. West J Med 1987;146:39-42.

59. Javed A, Tebben PJ, Fischer PR, Lieff AN. Female Athlete Triad and its components: Toward improved screening and management. Mayo Clin Proc 2013;88:996-1009.

60. Chen EC, Brzyski RG. Exercise and reproductive dysfunction. Fertil Steril 1999;71:1-6.

61. Berga TL, Marcus MD, Loucks TL, Hlastala S, Ringham R, Krohn MA. Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavioral therapy. Fertil Steril 2003;80:976-981.

62. Michopoulos V, Mancini F, Loucks TL, Berga SL. Neuroendocrine recovery initiated by cognitive behavioral therapy in women with functional hypothalamic amenorrhea: a randomized, controlled trial. Fertil Steril 2013;99:2084-2091. Epub 2013 Mar 16

63. Tschugguel W, Berga SL. Treatment of functional hypothalamic amenorrhea with hypnotherapy. Fertil Steril 2003;80:982-985.

64. Cann CE, Genant HK, Ettenger B, Gordan GS. Spinal mineral loss in oophorectomized women: determination by quantitative computed tomography. JAMA 1980;244:2056-2059.

65. Johansson BW, Kajl I, Küllander S, Lennér HC, Åstedt B. On some late effects of bilateral oophorectomy in the age range 15-30 years. Acta Obstet Gynecol Scand 1975;54:449-461.

66. Liu SL, Lebrun CM. Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br J Sports Med 2006;40:11-24.

67. Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ, Ellis K. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol 1997;176:1015-1025.

68. Castelo-Branco C, Vicente JJ, Pons F, Martinez de Osaba MJ, Casals E, Vanrell JA. Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. J Reprod Med 2001;46:875-879.

69. De Creë C, Lewin R, Ostyn M. Suitability of ciprofloxacin acetate in the treatment of osteoporosis associated with athletic amenorrhea. Int J Sports Med 1988;9:187-192

70. Gulekli B, Davies MC, Jacobs HS. Effect of treatment on established osteoporosis in young women with amenorrhea. Clin Endocrinol (Oxf) 1994;41:275-281.
71. Haenggi W, Casez JP, Birkhaeuser MH, Lippuner K, Jaeger P. Bone mineral density in young women with long-standing amenorrhea: limited effect of hormone replacement therapy with ethinylestradiol and desogestrel. Osteoporos Int 1994;4:99-105.

72. Cumming DC. Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy. Arch Intern Med 1996;156:2193-2195.

73. Rickenlund A, Carlström K, Ekblom B, Brismar TB, Von Scholtz B, Hirschberg AL. Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinol Metab 2004;89:4364-4370. Epub 2004 Aug 24.

74. Gibson JH, Mitchell A, Reeve J, Harries MG. Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study. Osteoporos Int 1999;10:284-289.

75. Gremion G, Rizzoli R, Slosman D, Theinz G, Bonjour JP. Oligoamenorrheic long-distance runners may lose more bone in spine than in femur. Med Sci Sports Exerc 2001;33:15-21.

76. Zanker CL, Cooke CB, Truscott JG, Oldroyd B, Jacobs HS. Annual changes of bone density over 12 years in an amenorrheic athlete. Med Sci Sports Exerc 2004;36:137-142.

77. Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 2011;26:2430-2438.

78. Harel Z, Riggs S. Transdermal versus oral administration of estrogen in the management of lumbar spine osteopenia in an adolescent with anorexia nervosa. J Adolesc Health 1997;10:179-182.

79. Ackerman KE, Singhal V, Baskaran C, Slattery M, Campoverde Reyes KJ, Toth A, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M. Oestrogen replacement improves bone mineral density in oligo-amenorrheic athletes: a randomised clinical trial. Br J Sports Med 2019;53:229-236. Epub 2018 Oct 9.

80. Hergenroeder AC. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995;126:683-689.

81. Vescovi JD, Jamal SA, De Souza MJ. Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature. Osteoporos Int 2008;19:465-478. Epub 2008 Jan 8.

82. Martin KA, Hall JE, Adams JM, Crowley WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropin amenorrhea. J Clin Endocrinol Metab 1993;77:125-129.

83. Christou F, Petteloud N, Gomez F. The induction of ovulation by pulsatile administration of GnRH: an appropriate method in hypothalamic amenorrhea. Gynecol Endocrinol 2017;33:598-601. Epub 2017 Mar 6.

84. Dumont A, Dewailly D, Plouvier P, Carteau-Jonard S, Robin G. Comparison between pulsatile GnRH therapy and gonadotropins for ovulation induction in women with both functional hypothalamic amenorrhea and polycystic ovarian morphology. Gynecol Endocrinol 2016;32:999-1004. Epub 2016 Jun 3.

85. Gompel A, Mauvais-Jarvis P. Induction of ovulation with pulsatile GnRH in hypothalamic amenorrhea. Hum Reprod 1988;3:473-477.

86. Wildt L, Leyendecker G, Sir-Petermann T, Wäibel-Treber S. Treatment with naltrexone in hypothalamic ovarian failure: induction of ovulation and pregnancy. Hum Reprod 1993;8:350-358.

87. Remorgida V, Venturini PL, Anserini P, Salerno E, De Cecco L. Naltrexone in functional hypothalamic amenorrhea and in the normal luteal phase. Obstet Gynecol 1990;76:1115-1120.

88. Wildt L, Leyendecker G. Induction of ovulation by the chronic administration of naltrexone in hypothalamic amenorrhea. J Clin Endocrinol Metab 1987;64:1334-1335.

89. Leyendecker G, Wäibel-Treber S, Wildt L. Pulsatile administration of gonadotrophin releasing hormone and oral administration of naltrexone in hypothalamic amenorrhea. Hum Reprod 1993;8(Suppl 2):184-188.

90. O’Donnell E, Goodman JM, Harvey PJ. Clinical review: Cardiovascular consequences of ovarian disruption: A focus on functional hypothalamic amenorrhea in physically active women. J Clin Endocrinol Metab 2011;96:3638-3648. Epub 2011 Sep 28.

91. Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, Hodgson TK, Matthews KA, Pepine CJ, Reis SE, Reichek N, Rogers WJ, Pohost GM, Kelsey SF, Sopko G. WISE Study Group. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003;41:413-419.

92. Rickenlund A, Eriksson MJ, Schenck-Gustafsson K, Hirschberg AL. Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile. J Clin Endocrinol Metab 2005;90:1354-1359.

93. Rickenlund A, Eriksson MJ, Schenck-Gustafsson K, Hirschberg AL. Oral contraceptives improve endothelial function in amenorrheic athletes. J Clin Endocrinol Metab 2005;90:3162-3167.

94. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004;351:987-997.

95. Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brincker MR, Gao H, Arazamah K, Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA 2011;108:6585-6590. Epub 2011 Apr 4.

96. Jayasena CN, Nijjer GM, Chaudhri OB, Murphy KG, Rancer A, Lim A, Patel D, Mehta A, Todd C, Ramachandran R, Salem V, Stamp GW, Donaldson M, Ghatel MA, Bloom SR, Dhillon WS. Subcutaneous injection of kispeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab 2009;94:4315-4323. Epub 2009 Oct 9.

Gibson MES et al.

Functional Hypothalamic Amenorrhea